Leap Therapeutics Inc expected to post a loss of 11  cents a share - Earnings Preview

Cypherpunk Technologies

08/03/2022 19:31

* Leap Therapeutics Inc  LPTX.OQ   LPTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 10
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 18.4% decrease in revenue to $306 thousand from $375 thousand
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Leap Therapeutics
Inc is
for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of 9 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $5​, above​ its last closing price of $1.74. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.10       -0.11      -0.14     Missed  -25
 Jun. 30 2021  -0.13       -0.12      -0.12     Met     4
 Mar. 31 2021  -0.11       -0.11      -0.12     Missed  -13.2​
 Dec. 31 2020  -0.09       -0.09      -0.09     Met     -2.3
 ​​Sep.        -0.12       -0.13      -0.09     Beat    29.7
 30 2020                                                
 Jun. 30 2020  -0.19       -0.18      -0.12     Beat    33.3​
 Mar. 31 2020  -0.25       -0.24      -0.25     Missed  -2
 Dec. 31 2019  -0.33       -0.32      -0.33     Missed  -3.9
 This summary was machine generated March 8 at 19:31 GMT.  All
figures in US dollars  unless otherwise stated